Efficacy of lacosamide and phenytoin in status epilepticus: A systematic review
- 17 May 2021
- journal article
- review article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 144 (4) , 366-374
Abstract
Objectives To compare the evidence on efficacy, safety, tolerability, and impact on short term/long functional outcome of lacosamide (LCM) and phenytoin (PHT) in patients with status epilepticus. Materials & Methods We conducted a systematic literature search of relevant electronic databases using a suitable search strategy to identify studies directly comparing PHT and LCM, irrespective of dose and duration in patients with convulsive and/or nonconvulsive status epilepticus (SE). We used a standardized assessment form to extract information on the study design, data sources, methodologic framework, efficacy, and adverse events attributed to PHT and LCM from included studies and compared the efficacy and safety outcomes, using a fixed/random effect model. Results Five studies were found to be eligible for inclusion out of 192 search items, enrolling a total of 115 and 166 participants (predominantly with SE) in LCM and PHT arm, respectively. Baseline characteristics were comparable between both arms. The proportion with seizure control was comparable between both arms (57.3% in LCM vs. 45.7% in PHT arm, p = 0.28) and even in the subgroup analysis separately for convulsive and non-convulsive SE. Proportion with treatment-emergent adverse events (TEAE) were comparable in both (17.6% vs. 12.2%, p = 0.20), but serious adverse events (SAE) were higher in PHT arm (5.1% vs. 0.8%, p = 0.049). The proportion with all-cause mortality and survival with moderate-severe disability were comparable between both arms (p = 0.23 and 0.37, respectively). Conclusion LCM has comparable efficacy with fewer SAEs as compared to PHT for achieving seizure control in patients with SE.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysisSeizure: European Journal of Epilepsy, 2021
- Response to Carbamazepine in KCNQ2 Related Early Infantile Epileptic EncephalopathyIndian Journal of Pediatrics, 2018
- Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizuresAnnals of Neurology, 2018
- Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trialThe Lancet Neurology, 2017
- Lacosamide as adjunctive therapy in refractory epilepsy in adults: A systematic reviewSeizure: European Journal of Epilepsy, 2015
- Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessmentsBMC Medical Research Methodology, 2014
- The adverse event profile of lacosamide: A systematic review and meta‐analysis of randomized controlled trialsEpilepsia, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Newer antiepileptic drugs: advantages and disadvantagesBrain and Development, 2001
- Side effects and mortality associated with use of phenytoin for early posttraumatic seizure prophylaxisJournal of Neurosurgery, 1999